Nootropic Triple Stack
83
상호작용
3
72,129
advanced
May 17, 2026
개요
The Nootropic Triple Stack is designed for serious long-term cognitive optimization — combining Semax''s acute BDNF upregulation with Dihexa''s synaptogenesis and NAD+''s mitochondrial support to drive neuroplasticity, synaptic density, and cellular energy simultaneously. Semax provides the immediate BDNF increase — stimulating existing neurons to grow new connections, improving signal transmission, and protecting against neurodegeneration. As the most acutely potent BDNF-upregulating compound available, Semax creates the biological environment in which new learning and synaptic formation are most likely to occur. Dihexa is a hexapeptide derived from angiotensin that demonstrates extraordinary potency for HGF/Met signaling — a pathway crucial to synaptogenesis (the formation of new synaptic connections). Animal studies showed cognitive improvements in Alzheimer''s models at doses described as "several orders of magnitude more potent than BDNF." Dihexa works over longer timeframes than Semax and is taken less frequently — it builds new synaptic architecture over weeks rather than enhancing acute performance. NAD+ (nicotinamide adenine dinucleotide) is the foundational energy molecule for every cell in the body. Brain neurons are among the most metabolically demanding cells, and NAD+ decline with age directly impairs their function. IV or subcutaneous NAD+ supplementation restores cellular energy production, supports DNA repair, and activates sirtuins — the longevity proteins involved in cognitive aging. NAD+ also synergizes with BDNF signaling, providing the cellular energy required to support the synaptic growth that Semax and Dihexa promote. This stack is administered across different timeframes: Semax daily (acute BDNF), Dihexa three times weekly (chronic synaptogenesis), NAD+ weekly (mitochondrial restoration). It represents a comprehensive, layered approach to long-term cognitive enhancement rather than acute performance.
용량 프로토콜
600 mcg
1회 용량당
100 mcg
1회 용량당
500,000 mcg
1회 용량당
목표 및 증거
경고
- Dihexa has minimal human data. NAD+ IV should be administered by a qualified provider. This is an advanced protocol requiring careful monitoring.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.